8-K 1 a06-18334_18k.htm CURRENT REPORT OF MATERIAL EVENTS OR CORPORATE CHANGES

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

August 17, 2006

Date of Report (Date of
earliest event reported)

Poniard Pharmaceuticals, Inc.

(Exact Name of Registrant as Specified in Charter)

Washington

 

0-16614

 

91-1261311

(State or Other Jurisdiction

 

(Commission File No.)

 

(IRS Employer

of Incorporation)

 

 

 

Identification No.)

 

 

 

 

 

7000 Shoreline Court, Suite 270, South San Francisco, California

 

94080

(Address of principal executive offices)

 

(Zip Code)

 

(206) 281-7001

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 



 

Section 8 – Other Events

Item 8.01.

 

Other Events.

 

On August 17, 2006, Poniard Pharmaceuticals, Inc. announced that it had completed patient enrollment in its Phase II trial of picoplatin in small cell lung cancer.  See press release dated August 17, 2006, attached hereto as Exhibit 99.1 and incorporated herein by reference.

Item 9.01.

 

Financial Statements and Exhibits.

 

 

 

(d)

 

Exhibits.

 

 

99.1 - Press release dated August 17, 2006

 

1



 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Poniard Pharmaceuticals, Inc.

 

 

 

 

 

Dated: August 18, 2006

 

By:

/s/ Anna L. Wight

 

 

 

 

Name: Anna L. Wight

 

 

 

Title: Vice President, Legal

 

 

2



 

EXHIBIT INDEX

Exhibit No.

 

Description

99.1

 

Press Release dated August 17, 2006

 

3